Biotron's Vpu blockers clear first hurdle

Canberra-based anti-viral drug developer Biotron has completed acute toxicity tests of its lead anti-HIV drug candidates in mice and found their toxicity levels are within acceptable limits.

The anti-HIV compounds target the ion channel encoded by the Human Immunodeficiency Virus’ Vpu gene. The pore is thought to be critical to the ability of newly replicated virus particles to bud from the host cell’s outer membrane.

Biotron chemists have developed more than 160 versions of its anti-Vpu compounds, and selected six for a pre-clinical testing program to establish a “no observed adverse effect levels” (NOAEL) for each of them.

In a press release, the company said all six compounds were metabolised by the mice after oral dosing, without unacceptable toxic effects.

Biotron researchers are now conducting bioavailabilty studies as part of a series of preclinical tests to ensure the compounds’ safety and efficacy. Phase I/Iia clinical trials will then be undertaken in humans.

Biotron’s CEO, Dr Michelle Miller, said she found a high level of interest in the company’s anti-viral compounds among pharmaceutical and biotechnology company leaders at the recent BIO2004 biotechnology industry conference in San Francisco. Biotron is in discussions with several potential partners and collaborators.